19KA Stock Chart & Stats
€6.49
-€0.26(-3.85%)
At close: 4:00 PM EDT
€6.49
-€0.26(-3.85%)
Day’s Range― - ―
52-Week Range€5.20 - €12.70
Previous CloseN/A
Volume0.00
Average Volume (3M)10.00
Market Cap
€568.06M
Enterprise Value€613.76
Total Cash (Recent Filing)€256.69M
Total Debt (Recent Filing)€145.15M
Price to Earnings (P/E)3.4
Beta1.31
Next Earnings
Nov 11, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.41
Shares Outstanding77,944,320
10 Day Avg. Volume0
30 Day Avg. Volume10
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.07
Price to Sales (P/S)2.69
P/FCF Ratio4.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.99Price Target Upside84.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.44
Revenue Forecast (FY)€294.18M
Bulls Say, Bears Say
Bulls Say
Broad Dialysis-provider AccessCoverage of all five leading dialysis providers materially expands DefenCath’s access to the core customer base. Multi-year agreements can support protocol adoption and recurring demand, while the pilot offers a pathway to broader clinic penetration.
Strong Profitability And Cash GenerationHigh recent margins and free cash flow that nearly matches net income indicate strong earnings quality and internal funding capacity. This provides flexibility to support commercialization, pipeline investment and balance-sheet resilience without relying heavily on external capital.
Pipeline And Regulatory ExpansionPositive Phase III data and a defined regulatory path could expand CorMedix beyond DefenCath and diversify future revenue. If approved, REZZAYO may leverage existing commercial capabilities while strengthening the company’s long-term product portfolio.
Bears Say
Reimbursement UncertaintyDefenCath adoption and revenue depend partly on reimbursement economics for dialysis providers. Changes after TDAPA, delayed Medicare Advantage contracting or an unfavorable ESRD rule could pressure ordering patterns, especially among smaller providers.
Limited Earnings HistoryThe current earnings profile is not yet supported by a long operating record. Earlier losses, minimal revenue and negative cash flow make it harder to assess normalized margins and increase the risk that future results depend on sustained DefenCath execution.
Higher Operating-cost BaseThe Melinta acquisition and planned commercial expansion have materially increased the cost base. Continued hiring and launch preparation may reduce operating leverage before new products generate revenue, making profitability more dependent on successful integration and execution.
Cormedix News
19KA FAQ
What was Cormedix’s price range in the past 12 months?
Cormedix lowest stock price was €5.20 and its highest was €12.70 in the past 12 months.
What is Cormedix’s market cap?
Cormedix’s market cap is €568.06M.
When is Cormedix’s upcoming earnings report date?
Cormedix’s upcoming earnings report date is Nov 11, 2026 which is in 82 days.
How were Cormedix’s earnings last quarter?
Cormedix released its earnings results on Aug 13, 2026. The company reported €0.25 earnings per share for the quarter, beating the consensus estimate of €0.206 by €0.045.
Is Cormedix overvalued?
According to Wall Street analysts Cormedix’s price is currently Undervalued.
Does Cormedix pay dividends?
Cormedix does not currently pay dividends.
What is Cormedix’s EPS estimate?
Cormedix’s EPS estimate is -0.09.
How many shares outstanding does Cormedix have?
Cormedix has 77,944,320 shares outstanding.
What happened to Cormedix’s price movement after its last earnings report?
Cormedix reported an EPS of €0.25 in its last earnings report, beating expectations of €0.206. Following the earnings report the stock price went down -1.883%.
Which hedge fund is a major shareholder of Cormedix?
Currently, no hedge funds are holding shares in DE:19KA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cormedix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€11.99 (84.72% Upside)
€11.99 (84.72% Upside)
Blogger Sentiment
Bullish
DE:19KA Sentiment 84%
Sector Average 61%
Sector Average 61%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
257.90%
Trailing 12-Months
Company Description
Cormedix
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
19KA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial execution (notably large revenue and adjusted EBITDA growth), solid cash generation, strategic commercial agreements with all top 5 dialysis providers, and meaningful pipeline progress highlighted by positive Phase III data for REZZAYO and an anticipated sNDA submission. These positives were tempered by higher operating expenses (driven by the Melinta acquisition and planned commercial investments), uncertainty around post-TDAPA ordering patterns and final ESRD reimbursement, and the limited current visibility on the impact of the new LDO pilot and Medicare Advantage contracting. On balance, the magnitude of the operational and financial wins (large YoY revenue and EBITDA growth, strong cash flow, clear regulatory/pipeline momentum) outweighs the near-term expense increases and reimbursement uncertainties.View all DE:19KA earnings summaries19KA Stock 12 Month Forecast
Average Price Target
€11.99
▲(84.72% Upside)
Technical Analysis
Arbutus Biopharma
―
Immatics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Zenas BioPharma, Inc.
―